MEDIA

EDUCATION

Undergraduate Degree

BA
  • University of Vermont , 2001 , Burlington , VT

Medical School

  • University of Vermont , 2005 , Burlington , VT

Residency

Emergency Medicine
  • Emory University , 2008 , Atlanta , GA

Fellowship

Sports Medicine
  • Boston Children's Hospital , 2009 , Boston , MA

CERTIFICATIONS

  • American Board of Emergency Medicine

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Hallux Sesamoid Injury Characteristics in Young Athletes Presented to the Sports Medicine Clinic. Clin J Sport Med. 2021 Mar 01. View abstract
  2. Special Considerations for Growing Dancers. Phys Med Rehabil Clin N Am. 2021 Feb; 32(1):75-86. View abstract
  3. Part II: Comparison of Crossfit-Related Injury Presenting to Sports Medicine Clinic by Sex and Age. Clin J Sport Med. 2020 05; 30(3):251-256. View abstract
  4. Part I: Crossfit-Related Injury Characteristics Presenting to Sports Medicine Clinic. Clin J Sport Med. 2020 03; 30(2):102-107. View abstract
  5. The Evaluation of Strength, Flexibility, and Functional Performance in the Adolescent Ballet Dancer During Intensive Dance Training. PM R. 2019 07; 11(7):722-730. View abstract
  6. Body Mass Index and Menstrual Patterns in Dancers. Clin Pediatr (Phila). 2017 Jan; 56(1):49-54. View abstract
  7. Physical Activity Level and Symptom Duration Are Not Associated After Concussion. Am J Sports Med. 2016 Apr; 44(4):1040-6. View abstract
  8. Athletes Doing Arabesques: Important Considerations in the Care of Young Dancers. Curr Sports Med Rep. 2015 Nov-Dec; 14(6):448-54. View abstract
  9. "Nutcracker Fracture" in a Ballet Dancer Performing in The Nutcracker. J Dance Med Sci. 2015 Sep; 19(3):124-7. View abstract
  10. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol. 2015 Jul 23; 22(7):876-887. View abstract
  11. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget. 2015 Jun 30; 6(18):16623-37. View abstract
  12. Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. Cancer Res. 2015 Jun 01; 75(11):2305-15. View abstract
  13. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma. Adv Cancer Res. 2015; 127:283-306. View abstract
  14. Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic. Oncotarget. 2015 May 10; 6(13):10712-27. View abstract
  15. Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approach. Mol Pharmacol. 2015 Feb; 87(2):286-95. View abstract
  16. Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Cancer Res. 2014 Nov 01; 74(21):6224-35. View abstract
  17. Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV). J Cell Physiol. 2014 Jan; 229(1):34-43. View abstract
  18. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets. 2013 Jan; 17(1):61-75. View abstract
  19. Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anticancer Agents Med Chem. 2012 Nov; 12(9):1143-55. View abstract
  20. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol. 2012 May; 227(5):2145-53. View abstract
  21. MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Front Biosci (Landmark Ed). 2012 Jan 01; 17:1-15. View abstract
  22. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011 Oct; 20(10):1397-411. View abstract
  23. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A. 2011 May 24; 108(21):8785-90. View abstract
  24. Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res. 2010 Oct 19; 3:24. View abstract
  25. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev. 2010 Oct; 21(5):381-91. View abstract
  26. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One. 2009 Dec 31; 4(12):e8404. View abstract
  27. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. . 2007 Nov; 6(11):1717-25. View abstract